Who is sponsoring SELECT?

SELECT is sponsored by H. Jaap Bonjer, PhD.

What condition does SELECT study?

SELECT studies Colorectal Cancer.

What drugs are being tested in SELECT?

Interventions: Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B).

What is the status of SELECT?

SELECT is currently TERMINATED.

Last reviewed 2018-11-07 · How we verify

Perioperative Selective Decontamination of the Digestive Tract (SDD) in Elective Colorectal Cancer Patients: a Multicenter Randomized Clinical Trial (SELECT)

NCT01740947 Phase 4 TERMINATED

The primary objectives of this randomized clinical trial are to evaluate if perioperative SDD can reduce clinical anastomotic leakage rate and its septic consequences as well as other infectious complications. By reduction of septic complications long-term oncological outcome might simultaneously improve.

Details

Lead sponsor	H. Jaap Bonjer, PhD
Phase	Phase 4
Status	TERMINATED
Enrolment	485
Start date	2013-01
Completion	2017-03

Conditions

Colorectal Cancer

Interventions

Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)

Primary outcomes

anastomotic leakage and/or abscess — 30 days postoperatively
clinical and/or radiological evidence of anastomotic dehiscence requiring surgical or radiological (re)intervention.

Countries

Netherlands